Electronic Health Record Augmented LDL-Cholesterol Optimization and Control Via Active Lipid Engagement (EHR-LOCALE): A Quality Improvement Implementation Study

Condition(s) studied

Investigational drug(s) / intervention(s)

Pharmacist-led lipid optimization pathway: Referral to a centralized, pharmacist-led, telephone clinic for optimization of dyslipidemia management

Study summary

The purpose of this study is to determine whether a proactive, EHR-guided approach helps more individuals reach safe cholesterol levels, improves medication use, and reduces future heart attacks and strokes, compared to usual care.

The main question it aims to answer is:

• Does the EHR-LOCALE pathway increases the proportion of patients who reach the LDL-cholesterol target of \<1.8 mmol/L at 6 months?

Participants in the interventional group receive:

* Pharmacist contact
* Repeat lipid requisitions
* Review of medications, adherence, and side effects
* Treatment escalation according to national dyslipidemia guidelines

Eligibility

Primary outcome measure(s)

• Proportion of individuals who achieve guideline recommended low-density-lipoprotein (LDL) cholesterol target of <1.8 mmol/L at 6-months — From enrollment to the end of intervention at 6 months

Trial sites (2)

More University of Alberta trials in Canada

Other trials for the same condition